Patents by Inventor Fanny Daniel

Fanny Daniel has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20160066551
    Abstract: The present invention relates to a non human model animal for ulcerative colitis and its main complications such as primary sclerosing cholangitis and colorectal cancer. More particularly, the present invention relates to a transgenic non human animal model for ulcerative colitis and its main complications such as primary sclerosing cholangitis, and colorectal cancer comprising a targeted disruption in the IL10 and NOX1 genes so that IL10 and NOX1 are not expressed in said animal.
    Type: Application
    Filed: November 17, 2015
    Publication date: March 10, 2016
    Applicant: Institut National de la Sante et de la Recherche Medicale (INSERM)
    Inventors: Eric OGIER-DENIS, Xavier TRETON, Fanny DANIEL, Cecile GUICHARD, Eric PEDRUZZI, Yoram BOUHNIK, Yann HARNOY
  • Patent number: 9217156
    Abstract: The present invention relates to a non human model animal for ulcerative colitis and its main complications such as primary sclerosing cholangitis and colorectal cancer. More particularly, the present invention relates to a transgenic non human animal model for ulcerative colitis and its main complications such as primary sclerosing cholangitis, and colorectal cancer comprising a targeted disruption in the IL10 and NOX1 genes so that IL10 and NOX1 are not expressed in said animal.
    Type: Grant
    Filed: April 13, 2012
    Date of Patent: December 22, 2015
    Assignee: Institut National de la Sante et de la Recherche Medicale (INSERM)
    Inventors: Eric Ogier-Denis, Xavier Treton, Fanny Daniel, Cecile Guichard, Eric Pedruzzi, Yoram Bouhnik, Yann Harnoy
  • Publication number: 20140373186
    Abstract: The present invention relates to a non human model animal for ulcerative colitis and its main complications such as primary sclerosing cholangitis and colorectal cancer. More particularly, the present invention relates to a transgenic non human animal model for ulcerative colitis and its main complications such as primary sclerosing cholangitis, and colorectal cancer comprising a targeted disruption in the IL10 and NOX1 genes so that IL10 and NOX1 are not expressed in said animal.
    Type: Application
    Filed: April 13, 2012
    Publication date: December 18, 2014
    Applicant: Institut National de la Sante et de la Recherche Medicale (INSERM)
    Inventors: Eric Ogier-Denis, Xavier Treton, Fanny Daniel, Cecile Guichard, Eric Pedruzzi, Yoram Bouhnik, Yann Harnoy
  • Publication number: 20140031389
    Abstract: The present invention relates to screening methods and pharmaceutical compositions for the treatment of inflammatory bowel disease. More particularly, the present invention relates to a method for screening a plurality of test substances useful for the prevention or treatment of an inflammatory bowel disease comprising the steps consisting of (a) testing each of the test substances for its ability to restore the integrated stress response and (b) and positively selecting the test substances capable of restoring said integrated stress response. A further aspect of the invention relates to an agent capable of restoring the integrated stress response (ISR) for use in the treatment of an inflammatory bowel disease.
    Type: Application
    Filed: April 13, 2012
    Publication date: January 30, 2014
    Applicant: INSERM (INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MDEICALE)
    Inventors: Eric Ogier-Denis, Xavier Treton, Eric Pedruzzi, Fanny Daniel